The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...
In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback